AviadoBio Advances ASPIRE-FTD Trial with Second Cohort Completion

Portfolio | May 01, 2025 | SV Health Investors, LLC

AviadoBio, a pioneering gene therapy firm focusing on neurodegenerative disorders, has successfully completed the second cohort in its Phase 1/2 ASPIRE-FTD clinical trial. This trial is evaluating AVB-101, an investigational gene therapy for frontotemporal dementia (FTD) with GRN gene mutations. The therapy, which bypasses the blood-brain barrier via a direct neurosurgical procedure, aims to restore progranulin levels in the brain, potentially halting or reversing disease progression. After dosing the sixth patient, the company has reported no clinically significant safety issues and is preparing to start a third cohort in 2025, with biomarker data expected in 2026. The trial is gathering participants from the U.S., Spain, Poland, Sweden, and the Netherlands, with plans to include more countries. AviadoBio, founded from research at King's College London and a part of SV Health Investors' portfolio, collaborates with Astellas Pharma for global rights to AVB-101.

Sectors

  • Biotechnology
  • Healthcare
  • Pharmaceuticals

Geography

  • United States – The trial is recruiting participants in the U.S., and AviadoBio is based on research from institutions in the UK and operates internationally.
  • Europe – Participants are being recruited for the trial in European countries including Spain, Poland, Sweden, and the Netherlands.

Industry

  • Biotechnology – The article involves AviadoBio, which is a gene therapy company working on innovative treatments for neurodegenerative disorders.
  • Healthcare – The article discusses the development and clinical trials of AVB-101, a therapy for frontotemporal dementia, a key focus within the healthcare sector.
  • Pharmaceuticals – AVB-101, the investigational gene therapy, is under clinical trials which involves regulatory processes typical in the pharmaceutical industry.

Financials

    Participants

    NameRoleTypeDescription
    AviadoBioTargetCompanyA gene therapy company pioneering treatments for neurodegenerative disorders.
    SV Health Investors, LLCInvestorCompanyA private equity firm investing in healthcare companies, including AviadoBio.
    Astellas Pharma Inc.CollaboratorCompanyA pharmaceutical company collaborating with AviadoBio for the global rights to their gene therapy.
    David Cooper, M.D.Chief Medical OfficerPersonOversees the clinical development at AviadoBio.
    Lisa DeschampsCEOPersonChief Executive Officer of AviadoBio, leading the company’s strategic direction.